Likely cancer case surge raises health system worries
Australians are deeply worried about their cancer risk, with many believing the nation's health system is unprepared for the expected rise in cases.
More than 4.5 million new cancer cases are projected to be diagnosed in Australia before 2044, according to research from peak independent authority Cancer Council Australia.
A survey of more than 1500 Australians found almost half believed the nation's health system was unprepared for this rise in cases.
More than 70 per cent said they were concerned about developing cancer in their lifetime.
Young Australians were particularly worried, with 80 per cent of those aged 25 to 34 saying they were concerned about their cancer risk.
While cancer risk increased with age, Cancer Council policy director Megan Varlow said governments could do more to safeguard young people's future health.
"We know that 42 per cent of the total cancer burden is attributed to modifiable risk factors such as overweight and obesity, insufficient physical inactivity and UV exposure, all areas where prevention measures can make a significant difference," she said.
"While prevention is key to reducing cancer rates, we need to recognise that nearly one in two Australians will be affected by cancer in their lifetime."
The council is calling on the incoming federal government to commit to four key priorities to reduce the impact of cancer for all Australians.
This includes tackling the rise of obesity, investing in skin cancer prevention campaigns, increasing participation in the national bowel cancer screening program and providing equitable access to cancer care through improved services and support.
"Australians deserve to live healthy lives now and into the future," Ms Varlow said.
"This means having easy access to healthy foods to feed their families, living in environments that promote physical activity ... (and) feeling confident in looking after their health by protecting their skin from the sun or by taking a cancer screening test."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
5 hours ago
- Associated Press
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
NEEDHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Maha Radhakrishnan, M.D., to the Company's Board of Directors (Board) effective June 4, 2025. 'We are delighted to welcome Maha as a new member of Candel's Board,' said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. 'Her extensive industry experience will be extremely valuable as Candel advances its late-stage oncology programs toward potential approval and commercial development, with the aim of providing benefit to patients with significant unmet need.' Dr. Radhakrishnan brings significant experience in product development and commercialization that will be particularly valuable as Candel prepares for its Biologics License Application (BLA) submission for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026. 'I am honored to join the Board at this pivotal moment as Candel advances its innovative immunotherapy candidates across multiple cancer indications,' said Dr. Radhakrishnan. 'Candel's multimodal approach has the potential to address significant unmet needs in cancers that have historically been difficult to treat with conventional immunotherapies.' Dr. Radhakrishnan has over 20 years of experience advancing large strategic portfolios across various therapeutic areas through product development and commercialization within major biotechnology and pharmaceutical companies. Since August 2024, Dr. Radhakrishnan has served as an Executive Partner at Sofinnova Investments, a venture capital firm focused on life sciences, where she leads diligence across clinical-ready assets in multiple therapeutic areas and provides expertise to portfolio companies in product development and commercialization. Previously, Dr. Radhakrishnan served as Group Senior Vice President and Chief Medical Officer at Biogen Inc. Earlier in her career, she was Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi S.A. Dr. Radhakrishnan has also held leadership roles at Bioverativ, Inc., Bristol-Myers Squibb Company, UnitedHealth Group, Inc., and Cephalon, Inc. She received her M.D. with honors from the People's Friendship University in Moscow, Russia. 'Maha's expertise will be invaluable as we look forward to her contributions while we prepare to submit our Biologics License Application for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026,' said Paul B. Manning, Chairman of Candel's Board. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the submission of the Biologics License Application for CAN-2409 in intermediate-to-high-risk localized prostate cancer; and expectations regarding the therapeutic benefit of the Company's platforms. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. [email protected] Media Contact: Ben Shannon ICR Healthcare [email protected]
Tom's Guide
7 hours ago
- Tom's Guide
Scientists reveal how long you need to lift weights to build muscle — and it's not what you think
If you're looking to get noticeable muscle gains, I've got good news — you don't need to spend hours in the weights room to make it happen. In fact, new research suggests that sessions of just 30 minutes are enough. Below, we dig into the science below and look at the best exercises to prioritize if your goal is muscle growth. The small study, published in Medicine & Science in Sports & Exercise, had 42 healthy men and women follow a lifting program. The program involved nine different exercises, with one set of eight to 10 reps. The participants were assigned to two groups — one group would train to failure (a weightlifting term where you push yourself until you can't do any more reps). The other group would train until they had two reps in reserve (pushing themselves, but they finished still having energy to do more). The exercises targeted all of the major muscle groups and were completed in 30-minute sessions. Participants did two sessions a week for eight weeks. At the end of the eight weeks, researchers analyzed changes in the muscle thickness in areas of the body, as well as looking at measures of muscle strength and power. The researchers found that all of the participants saw muscle growth in the eight weeks. The changes were similar in the men and women who pushed themselves to failure, as with those who still had the energy to do more. Brad Schoenfeld, Ph.D is one of the co-authors of the study, and told Prevention the exact exercises the participants followed. Ready to build muscle, here's what to do in the gym: Get instant access to breaking news, the hottest reviews, great deals and helpful tips. A lot of these compound exercises target more than one muscle group at a time, allowing you to work your muscles harder, without spending hours in the gym. If you don't have a gym membership, grab a set of the best adjustable dumbbells and focus on doing pushups, squats, lunges, and deadlifts at home. Of course, there are several benefits to strength training, and even 20 minutes a couple of times a week is better than nothing. As well as building muscle, lifting weights can strengthen your bones and joints, help you lose or manage weight, and boost your mental wellbeing.
Yahoo
8 hours ago
- Yahoo
Atomic Kitten's Natasha Hamilton reveals skin cancer diagnosis
Atomic Kitten singer Natasha Hamilton has revealed she was diagnosed with skin cancer, saying she initially thought it was a 'mosquito bite'. The 42-year-old said she received the diagnosis last year after feeling an itch on her back following a holiday in Majorca while speaking on Good Morning Britain. She said: 'I'd been on holiday, and I wasn't actually in the sun a lot, because my baby was only about five months old, and I was breastfeeding. "Were you using sunbeds a lot?" Atomic Kitten singer Natasha Hamilton says she had a 'massive wake up call' after she was diagnosed with skin cancer. In 2024, Natasha found this suspicious mole on her back, which was subsequently diagnosed as what's called a 'basal-cell… — Good Morning Britain (@GMB) June 6, 2025 'And one afternoon I had her on my lap, and my back was in the sun and I burnt, and I don't know whether it was later that day or the next day, I had, like an itchy spot on my back, and I just thought it was a mosquito bite. 'Didn't think nothing, you don't get to look at your back very often, do you? It's tucked away. 'I felt it and went, 'oh, mosquito bite', it wasn't until maybe four weeks later, when I was at home and it was itching, and I was like, hang on a minute that seems a bit long for a mosquito bite. 'I asked my husband to have a look, and he went, 'oh, that's not a bite', and he took the picture, and when I looked at it, I went, 'okay, I think I know what that is'. 'Originally it had just been a dark freckle that I'd had on my back for many years, it wasn't raised, it wasn't a mole, it was just a freckle.' Hamilton went on to say she was later diagnosed with a 'basal-cell carcinoma', and added that she thought her use of sunbeds during her early days in the girl group in the late 1990s and early 2000s could have contributed. She added: 'People of my age will probably feel the same, or remember, if you were going on a night out you used a sunbed because you wanted that sunkissed look to make yourself feel good and give you a bit of confidence. 'If I was going to do something like Top Of The Pops or a big TV show, I'd want my look sunkissed, so we would go to the sunbeds. 'There was a sunbed shop based in the hotel that we stayed in all the time in London, and I'd use tan accelerators, and I can honestly say I don't think there was ever a time when I went on a sunbed that I didn't burn. 'Looking back now, because I'm type one skin anyway, I'm not supposed to be in such intense sun.' Hamilton's mother Maria was diagnosed with the same type of cancer after Hamilton noticed a mark on her face, and urged her to get it checked. She said her mother was initially told by doctors that the patch of skin was 'nothing', before she urged her to ask to be referred to a dermatologist a year later, who told her it was skin cancer 'straight away', before arranging for her to have them removed. Speaking in 2022, the singer, who has four children, said she had changed her lifestyle to lower the risk of increasing her chances of skin cancer following her mother's diagnosis. As part of Atomic Kitten alongside Kerry Katona and Liz McClarnon, before Katona was later replaced by Jenny Frost, Hamilton scored 13 UK top 10 singles and four UK top 10 albums – they are best known for the songs Whole Again and Eternal Flame.
